ArticleAnnals of translational medicine2017
Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers.
Article in Annals of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Role of circulating tumor cells in diagnosis of lung cancer: a systematic review and meta-analysis.The Journal of international medical research · 2021Pooled it
- Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer.Nature reviews. Clinical oncology · 2021Review
- Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.Molecular oncology · 2021Review
- Mutation differences in circulating tumor DNAs from non-small cell lung cancer patients between Uygur and Han populations.Medicine · 2021Article
- Oncogenic Genetic Alterations in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China.Cancer management and research · 2020Article
- A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.Journal of the National Cancer Institute · 2019Article
- [Liquid biopsy in tumor diagnostics : Applications, perspectives, and limitations of the "cancer liquidome"].Der Pathologe · 2019Review
Corrections and comments
- Comment on
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
The current standard of adjuvant therapies for patients with early stage non-small-cell lung cancers largely depends on the stage of disease. Liquid biopsy for circulating tumor DNA (ctDNA) has the potential to detect minimal residual disease, depict genomic evolution, guide precision medicine to individual patients and revolutionize the management of early stage lung cancers. In light of the seminal work published by Abbosh and colleagues, we discuss the potential paradigm changing clinical implications of ctDNA, the biological and technological challenges to consider, and the future of ctDNA driven therapeutic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.